Integrating Clinical and Translational Research Networks-Building Team Medicine - Series 2
The previous Special Issue of the Journal of Clinical Medicine, 'Integrating Clinical and Translational Research Networks-Building Team Medicine', which highlighted our collective experience from the City of Hope and was published in 2020, was a huge success. Buoyed by the enthusiastic res...
Format: | eBook |
---|---|
Language: | English |
Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
LEADER | 05965namaa2201525uu 4500 | ||
---|---|---|---|
001 | doab113918 | ||
003 | oapen | ||
005 | 20230911 | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 230911s2023 xx |||||o ||| 0|eng d | ||
020 | |a 9783036584720 | ||
020 | |a 9783036584737 | ||
020 | |a books978-3-0365-8473-7 | ||
024 | 7 | |a 10.3390/books978-3-0365-8473-7 |2 doi | |
040 | |a oapen |c oapen | ||
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
072 | 7 | |a MJCL |2 bicssc | |
720 | 1 | |a Salgia, Ravi |4 edt | |
720 | 1 | |a Kulkarni, Prakash |4 edt | |
720 | 1 | |a Kulkarni, Prakash |4 oth | |
720 | 1 | |a Salgia, Ravi |4 oth | |
245 | 0 | 0 | |a Integrating Clinical and Translational Research Networks-Building Team Medicine - Series 2 |
260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
300 | |a 1 online resource (230 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
520 | |a The previous Special Issue of the Journal of Clinical Medicine, 'Integrating Clinical and Translational Research Networks-Building Team Medicine', which highlighted our collective experience from the City of Hope and was published in 2020, was a huge success. Buoyed by the enthusiastic response from our peers and colleagues, we have embarked on bringing out Volume 2. The basic theme is the same-namely, integrating academic medical centers with the clinical network in various geographic locations to ensure that all patients, regardless of their physical proximity to major medical institutions, can benefit from recent clinical advances. As in the previous volume on the importance of including basic research scientists, our aim here is to highlight translational research approaches that leverage the combined knowledge, skills, experience, expertise, and vision of clinicians in academic medical centers, their affiliated community centers, and hospitals, together with those of basic research scientists. However, here we also strive to include bioinformaticians and data scientists. We look forward to sharing our team medicine experience with our colleagues around the world and trust that they will find the approach described in the articles included in this Special issue useful for guiding their approaches for treating cancer patients. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine and Nursing |2 bicssc | |
650 | 7 | |a Oncology |2 bicssc | |
653 | |a adaptive therapy | ||
653 | |a advanced soft tissue sarcoma | ||
653 | |a artificial intelligence | ||
653 | |a ATM mutation | ||
653 | |a brain metastases | ||
653 | |a BRIP1 mutation | ||
653 | |a cancer disparities | ||
653 | |a cancer prevention | ||
653 | |a cancer systems biology | ||
653 | |a care satisfaction | ||
653 | |a cisplatin | ||
653 | |a City of Hope | ||
653 | |a clinical care network | ||
653 | |a clinical network systems biology | ||
653 | |a clinical trials | ||
653 | |a collaboration | ||
653 | |a colorectal cancer survivor | ||
653 | |a combinational therapy | ||
653 | |a community clinical network | ||
653 | |a community practice | ||
653 | |a complex case discussions | ||
653 | |a continuous therapy | ||
653 | |a cutaneous cancers | ||
653 | |a decision support | ||
653 | |a delivery of health care | ||
653 | |a drug resistance | ||
653 | |a drug tolerance | ||
653 | |a eco-evolutionary | ||
653 | |a EGFR | ||
653 | |a emergency utilization | ||
653 | |a endometrial cancer | ||
653 | |a epigenetics | ||
653 | |a genetic/nongenetic | ||
653 | |a genomic-driven | ||
653 | |a group behavior | ||
653 | |a gut microbiome | ||
653 | |a IDPs | ||
653 | |a imaging | ||
653 | |a immune checkpoint inhibitors | ||
653 | |a immunotherapy | ||
653 | |a implementation | ||
653 | |a implementation science | ||
653 | |a integration | ||
653 | |a integrative oncology | ||
653 | |a intermittent therapy | ||
653 | |a intrinsically disordered proteins | ||
653 | |a LDCT | ||
653 | |a leptomeningeal metastases | ||
653 | |a low dose Ct scans | ||
653 | |a lung cancer screening | ||
653 | |a mathematical modeling | ||
653 | |a melanoma | ||
653 | |a metastasis-directed therapy | ||
653 | |a Midwest Sarcoma Trials Partnership | ||
653 | |a minority health | ||
653 | |a multidisciplinary tumor board | ||
653 | |a n/a | ||
653 | |a NET VITALS | ||
653 | |a neuroendocrine tumors | ||
653 | |a non-small cell lung cancer | ||
653 | |a Olaparib | ||
653 | |a oligometastatic | ||
653 | |a oncology | ||
653 | |a oncology pathways | ||
653 | |a oncolytic virotherapy | ||
653 | |a pandemic | ||
653 | |a PARP inhibition | ||
653 | |a pathologic complete response | ||
653 | |a pathways to success | ||
653 | |a personalized medicine | ||
653 | |a phase 1 | ||
653 | |a phenotype switching | ||
653 | |a POLE mutation | ||
653 | |a precision medicine | ||
653 | |a prostate cancer | ||
653 | |a PSMA PET | ||
653 | |a RAD51C mutation | ||
653 | |a renal cell carcinoma | ||
653 | |a sarcoma treatment | ||
653 | |a SARS-CoV-2 | ||
653 | |a self-assessment | ||
653 | |a smoking cessation | ||
653 | |a subspecialty expertise | ||
653 | |a T-VEC | ||
653 | |a targeted therapy | ||
653 | |a team medicine | ||
653 | |a Team Medicine | ||
653 | |a TMB high | ||
653 | |a tobacco control | ||
653 | |a translational research | ||
653 | |a tumor board | ||
793 | 0 | |a DOAB Library. | |
856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/113918 |7 0 |z Open Access: DOAB: description of the publication |
856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/7761 |7 0 |z Open Access: DOAB, download the publication |